Contineum Therapeutics, Inc. CTNM
Contineum Therapeutics, Inc. (Nasdaq: CTNM) is a respiratory drug developer. Its lead program, PIPE-791, is in Phase 2 for Idiopathic pulmonary fibrosis (IPF). Its next catalyst on record is PIPE-791 (PROPEL-IPF): Phase 2 trial completion (June 2028).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PIPE-791 (PROPEL-IPF) — Phase 2 trial completion (June 2028). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PIPE-791 | Idiopathic pulmonary fibrosis (IPF) | small molecule | Phase 2 |
| PIPE-307 (JNJ-89495120) | Major depressive disorder (MDD) | small molecule | Phase 2 |
| PIPE-791 | Chronic pain (osteoarthritic pain or chronic low back pain) | small molecule | Phase 1 |
| CTX-343 | Not disclosed | small molecule | Phase 1 |
Recent results and decisions
- Jul 30, 2026completed enrollment Johnson & Johnson completed enrollment of 107 participants in the Phase 2 MOONLIGHT-1 trial of PIPE-307/JNJ-5120 in MDD in June 2026.
Johnson & Johnson completed enrollment of 107 adult participants for its Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in June 2026.
Filing - May 5, 2026met Exploratory randomized Phase 1b met its primary objective of safety and tolerability, with pain improvements numerically greater than placebo (no figures given); topline originally reported April 30, 2026.
The trial met its primary objective of assessing safety and tolerability, demonstrating an adverse event profile generally consistent with previous PIPE-791 clinical trials.
Filing - Mar 5, 2026started Patient dosing initiated in PROPEL-IPF, a global 26-week randomized Phase 2 trial of PIPE-791 in ~324 IPF patients (primary endpoint change in FVC).
Contineum has initiated patient dosing in PROPEL-IPF, a global Phase 2 clinical trial evaluating PIPE-791 for the treatment of patients with IPF.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.